Two Onc Docs
Metastatic Breast Cancer 2024 UPDATE
Oct 21, 2024
Dr. Eleonora Teplinsky, a board-certified oncologist specializing in breast and gynecologic oncology, shares vital updates on metastatic breast cancer treatment. Dive into the latest systemic therapies for ER-positive cases, including endocrine therapy and CDK4-6 inhibitors. Discover new strategies for premenopausal women and the use of triplet therapy for PIK3CA mutations. Learn about advancements in HER2-positive patients with innovative drugs and the importance of molecular testing. Gain insights into managing toxicities and enhancing patient care.
20:14
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The standard first-line treatment for ER+ metastatic breast cancer combines endocrine therapy with CDK4-6 inhibitors, emphasizing the importance of ovarian suppression for premenopausal women.
- Toxicities from CDK4-6 inhibitors like cytopenias necessitate regular monitoring and dose adjustments, while treatment for triple-negative breast cancer hinges on PD-L1 status and may include immunotherapy options.
Deep dives
Key First-Line Treatments for ER Positive Metastatic Breast Cancer
The standard first-line treatment for estrogen receptor positive (ER+) metastatic breast cancer involves the use of endocrine therapy combined with a CDK4-6 inhibitor. Typically, this can be an aromatase inhibitor or fulvestrant, with the most common CDK4-6 inhibitors being ribocyclob, palbocyclob, and abamacyclob. Newly available combinations also include a triplet regimen for patients with PIC3CA mutations who have experienced recurrence. Premenopausal women may require ovarian suppression along with these therapies to enhance treatment efficacy.
